Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* 40 - 75 years of age~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* COPD diagnosis~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* Patients with established clinical history of COPD and severity defined as a post-ipratropium FEV1/FVC ratio of ≤0.70 and FEV1 ≥50 and ≤85% of predicted normal at Screening~* Must demonstrate reversibility to ipratropium demonstrated by a \>200 mL improvement over baseline and/or \>12% and \>150 mL improvement over baseline~* Patients willing to stay at study site for at least 24 hours on each test day~Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 24 weeks of Screening~* Unable to perform acceptable spirometry~* Poorly controlled COPD in prior 6-weeks, defined as the occurrence of acute worsening of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring treatment prescribed by a physician~* Clinically significant medical conditions~* Symptomatic prostatic hypertrophy or bladder neck obstruction~* Known narrow-angle glaucoma~* Lower respiratory tract infection requiring antibiotics in past 6 weeks~* Clinically significant abnormal ECG~* Clinically significant uncontrolled hypertension~* Positive Hepatitis B surface antigen or Hepatitis C antibody~* Cancer that has not been in complete remission for at least 5 years~* History of hypersensitivity to any beta2-agonists or anticholinergics~* History of severe milk protein allergy~* Known or suspected history of alcohol or drug abuse~* Medically unable to withhold short acting bronchodilators for 6-hours~* Use of the medications below in specified time interval prior to Screening: 3 months: depot corticosteroids, intra-articular corticosteroids; 6 weeks: oral corticosteroids, antibiotics administered for a COPD exacerbation; and 1 month: P-glycoprotein inhibitors, CYP450 3A4 inhibitors, ICS \>1000 μg/day of fluticasone propionate or equivalent~* The following COPD medications need to be stopped and switched to appropriate replacement therapies: tiotropium, oral beta2 agonists, LABAs, combination corticosteroid/LABAs, theophylline, leukotriene inhibitors,cromoglycate and nedocromil~* Use of the following medications is prohibited: tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, beta-adrenergic antagonists, anticonvulsants (barbiturates, hydantoins, and carbamazepine and phenothiazines~* Receiving long-term-oxygen or nocturnal oxygen therapy for \>12 hours a day~* Diagnosis of sleep apnea that is uncontrolled~* Participation in acute phase of pulmonary rehabilitation in prior 4 weeks~* Will enter acute phase of pulmonary rehabilitation program during study~* Unable to comply with study procedures~* Affiliated with Investigator site~* Questionable validity of consent~* Use of investigational study drug/participation in clinical study in the last 30 days or 5 half lives prior to Screening, whichever is longer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PT001 18 mcg (Type: EXPERIMENTAL): Inhaled PT001 18 mcg
- PT001 36 mcg (Type: EXPERIMENTAL): Inhaled PT001 36 mcg
- PT001 72 mcg (Type: EXPERIMENTAL): Inhaled PT001 72 mcg
- PT001 144 mcg (Type: EXPERIMENTAL): Inhaled PT001 144 mcg
- Inhaled Placebo (Type: PLACEBO_COMPARATOR): Inhaled Placebo
- Tiotropium Handihaler (Type: ACTIVE_COMPARATOR): Tiotropium 18 mcg administered via Handihaler

Based on this trial design, predict the completion outcome and termination type (if applicable).